相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
Tsutomu Takashima et al.
SPRINGERPLUS (2016)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter A. Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
Kristi McIntyre et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states
T. Yoshida et al.
BRITISH JOURNAL OF CANCER (2014)
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
Yasuhiro Funahashi et al.
CANCER SCIENCE (2014)
Gene Expression Profiling Reveals Epithelial Mesenchymal Transition (EMT) Genes Can Selectively Differentiate Eribulin Sensitive Breast Cancer Cells
Zoltan Dezso et al.
PLOS ONE (2014)
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
K. Aogi et al.
ANNALS OF ONCOLOGY (2012)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2012)
Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer
N. P. A. Devika Gunasinghe et al.
CANCER AND METASTASIS REVIEWS (2012)
The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Elias Pean et al.
CLINICAL CANCER RESEARCH (2012)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
Jennifer A. Smith et al.
BIOCHEMISTRY (2010)
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Linda T. Vahdat et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Kornelia Polyak et al.
NATURE REVIEWS CANCER (2009)
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Tatiana Okouneva et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Epithelial-mesenchymal transition and the invasive potential of tumors
Nancy Gavert et al.
TRENDS IN MOLECULAR MEDICINE (2008)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
MA Jordan et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389
G Kuznetsov et al.
CANCER RESEARCH (2004)
分享论文
